Clinical trials: Kidney Transplant Failure and Rejection, active
Kidney Transplant Failure and Rejection
Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)
Background: Subclinical inflammation, including borderline lesions (BL), is very common (30-40%) after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular atrophy…
- Trial name
- NCT04936282
- Testing
- Grafalon, Normal Treatment
- Where
- 4 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias
Kidney Transplant Failure and Rejection
Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection
Background: Long-term success of organ transplantation is limited by the inexorable loss of graft function due to rejection. Prevalent dogma defends that allograft rejection is exclusively mediated by the adaptive immune system…
- Trial name
- STARR (NCT03955172)
- Testing
- Everolimus
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Acute Rejection of Renal Transplant, Graft Failure
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
Acute rejection after kidney transplantation should ideally be diagnosed prior to immunologic injury in a non-invasive fashion in order to improve long-term graft function.
- Trial name
- NCT05084768
- Testing
- Donor-derived cell-free DNA
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Loma Linda University
End-stage Renal Disease (ESRD), Kidney Transplantation
Microbiota Changes Related to Outcomes in Kidney Transplantation
Chronic kidney disease affects approximately 10% of the world population. End-stage renal disease (ESRD) is associated with immune dysregulation, chronic inflammation, and alteration of the gut and urinary microbiota.
- Trial name
- MICRO-KT (NCT07893691)
- Testing
- Fecal samples, Urinary sample, Blood samples
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Kidney Disease, End-Stage, Donor Specific Antibodies
Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant
In spite of conventional immunosuppression with lymphocyte-depleting induction followed by tacrolimus- and mycophenolate-based regimens, African American (AA) renal transplant recipients experience higher rates of acute rejection…
- Conditions
- Kidney Disease, End-Stage, Donor Specific Antibodies, Acute Rejection of Renal Transplant
- Trial name
- NCT04665310
- Testing
- Envarsus XR
- Volunteers
- 46 people
- Sponsor
- The Methodist Hospital Research Institute
BK Viremia, Kidney Transplant Infection
A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients
BEAT-BK will see the effect of immunosuppression reduction/modification with and without IVIG on BKPyV infection, allograft function, allograft loss, acute transplant rejection, immunosuppression load and death in kidney and…
- Conditions
- BK Viremia, Kidney Transplant Infection, Kidney Transplant Failure and Rejection
- Trial name
- BEAT-BK (NCT05325008)
- Testing
- Immunosuppression reduction/modification + intravenous immunoglobulin, Immunosuppression reduction/modification
- Where
- 13 sites in Australia
- Volunteers
- 280 people
- Sponsor
- The University of Queensland
End-Stage Renal Disease, End Stage Renal Disease on Dialysis
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
This clinical trial investigates the transplantation of donor kidneys that have been genetically modified ex vivo using CRISPR-Cas9 genome editing to reduce immunogenicity and transplant rejection.
- Conditions
- End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection
- Trial name
- NCT07053462
- Testing
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney, Kidney Transplantation with Standard Care
- Where
- China
- Volunteers
- 90 people
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Kidney Diseases, Kidney Transplant
TreaT-Assay: the New Frontier for the Diagnosis of Acute Rejection in Kidney Transplantation
Kidney transplantation is the standard therapy for end-stage renal disease. Acute rejection (AR) or chronic rejection along with reactive donor immunity, which counteracts organ acceptance, are among the greatest medical…
- Conditions
- Kidney Diseases, Kidney Transplant, Kidney Disease, End-Stage
- Trial name
- NCT06801262
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
End Stage Kidney Disease, Immunological Tolerance
Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants
The study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function…
- Conditions
- End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
- Trial name
- NCT05525507
- Testing
- Conditioning and Stem cell infusion
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Kidney Transplant Rejection, End Stage Renal Disease
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
This long-term follow-up study is being conducted to collect long-term (up to 15 years post-infusion) safety and tolerability data from subjects enrolled in studies evaluating TX200-TR101.
- Trial name
- NCT05987527
- Testing
- Blood sample
- Where
- 5 sites in Belgium, Netherlands and 1 more
- Volunteers
- 11 people
- Sponsor
- Sangamo Therapeutics
Kidney Transplant Rejection
Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation
This study will evaluate the efficacy and safety of tegoprubart compared with tacrolimus in adult participants undergoing first kidney transplantation.
- Trial name
- LEGACY (NCT07835581)
- Testing
- Tegoprubart, Tacrolimus
- Volunteers
- 620 people
- Sponsor
- Eledon Pharmaceuticals
End Stage Kidney Disease, Immunological Tolerance
Immunological Tolerance in Patients With Mismatched Kidney Transplants
This study seeks to determine if administration of the drug belumosudil (KD025) will be safe and improve transplant tolerance in subjects undergoing combined Human Leukocyte Antigen (HLA) single haplotype-matched related or 0-3…
- Conditions
- End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
- Trial name
- NCT05806749
- Testing
- Donor CD34+, CD3+. and belumosudil
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Los Angeles
Organ Transplant Failure or Rejection, Brain Death
Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)
The investigators hypothesize that preconditioning neurologically deceased organ donors with the calcineurin inhibitor tacrolimus will improve short and long-term transplant survival without causing harm.
- Conditions
- Organ Transplant Failure or Rejection, Brain Death, Ischemic Reperfusion Injury
- Trial name
- CINERGY (NCT05148715)
- Testing
- Tacrolimus
- Where
- 9 sites in Canada
- Volunteers
- 414 people
- Sponsor
- Université de Sherbrooke
Kidney Transplantation
Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.
Imlifidase is a recombinant cysteine protease derived from Streptococcus pyogenes and produced in Escherichia coli, which has the ability to cleave and degrade all human IgGs.
- Trial name
- ISKIA (NCT07379957)
- Where
- 20 sites in France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Bordeaux
Renal Failure , Chronic, Graft Failure
Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure
The goal of this clinical trial is to compare the degree of HLA sensitization at 2 years in patients with late renal graft failure (> 3 months) when receiving reduced immunosuppressant treatment versus stopping immunosuppression…
- Conditions
- Renal Failure , Chronic, Graft Failure, Graft Rejection, Allograft
- Trial name
- NCT06676696
- Testing
- Continue low dose calcineurin inhibitor (CNI), Calcineurin inhibitor withdrawal at 6 months
- Where
- Spain
- Volunteers
- 202 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Kidney Transplantation
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
The goal of this multi-national, multi-center, open-label, randomized Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor…
- Trial name
- RETIRE (NCT06552169)
- Testing
- Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
- Where
- 7 sites in United States, Taiwan
- Volunteers
- 34 people
- Sponsor
- Singulera Therapeutics Inc.
Kidney Transplant Rejection
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
This study will evaluate the long term safety and efficacy of AT-1501 (tegoprubart) compared with tacrolimus in patients undergoing kidney transplantation.
- Trial name
- NCT06126380
- Testing
- AT-1501, Tacrolimus
- Where
- 43 sites in United States, Australia and 6 more
- Volunteers
- 132 people
- Sponsor
- Eledon Pharmaceuticals
Renal Transplant Failure and Rejection
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease.
- Trial name
- MODERNIZE1 (NCT07508787)
- Testing
- Siplizumab, Rabbit anti-thymocyte globulin
- Where
- 24 sites in United States, Brazil and 1 more
- Volunteers
- 120 people
- Sponsor
- Nefro Avillion Clinical Development, LLC
Prevention of Rejection in Kidney Transplant
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
- Trial name
- NCT05027906
- Testing
- AT-1501
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 48 people
- Sponsor
- Eledon Pharmaceuticals
Graft Failure, Death
European Transplant Registry of Senior Renal Transplant Recipients on Advagraf
SENIOR transplant Registry European transplant registry of senior renal transplant recipients (above the age of 65 years) receiving initial immunosuppression with tacrolimus once daily, mycophenolate and steroids to investigate…
- Conditions
- Graft Failure, Death, Acute Rejection of Renal Transplant, Infections
- Trial name
- SENIOR (NCT02558452)
- Testing
- Tacrolimus once daily (Advagraf)
- Volunteers
- 1,000 people
- Sponsor
- Klemens Budde